Gia Han Le, Angela T H Kwan, Ziji Guo, Sabrina Wong, Sebastian Badulescu, Hartej Gill, Kayla M Teopiz, Shakila Meshkat, Felicia Ceban, Lee Phan, Mehala Subramaniapillai, Joshua D Di Vincenzo, Joshua D Rosenblat, Rodrigo B Mansur, Giacomo d'Andrea, Roger Ho, Taeho Greg Rhee, Roger S McIntyre
BACKGROUND: Individuals who have recovered from the acute stage of SARS-CoV-2 infection may be at risk of developing post-COVID-19 condition (PCC), characterized by a spectrum of persisting, non-specific, and functionally impairing symptoms across multiple organ systems. Obesity has been implicated as a risk factor for PCC, mediated by chronic systemic inflammation. The foregoing has also been separately reported to mediate cognitive dysfunction in PCC. METHODS: This is a post-hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial evaluating vortioxetine treatment for cognitive impairments in persons with PCC who received vortioxetine or placebo for eight weeks...
April 12, 2024: Acta Neuropsychiatrica